Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma
Michael Dickinson, Javier Briones, Alex F Herrera, Eva González-Barca, Nilanjan Ghosh, Raul Cordoba, Sarah C Rutherford, Eirini Bournazou, Emily Labriola-Tompkins, Izolda Franjkovic, Evelyne Chesne, Jurriaan Brouwer-Visser, Katharina Lechner, Barbara Brennan, Eveline Nüesch, Mark DeMario, Dominik Rüttinger, Martin Kornacker, Martin Hutchings, Michael Dickinson, Javier Briones, Alex F Herrera, Eva González-Barca, Nilanjan Ghosh, Raul Cordoba, Sarah C Rutherford, Eirini Bournazou, Emily Labriola-Tompkins, Izolda Franjkovic, Evelyne Chesne, Jurriaan Brouwer-Visser, Katharina Lechner, Barbara Brennan, Eveline Nüesch, Mark DeMario, Dominik Rüttinger, Martin Kornacker, Martin Hutchings
Abstract
Bromodomain and extraterminal (BET) proteins are transcriptional activators for multiple oncogenic processes in diffuse large B-cell lymphoma (DLBCL), including MYC, BCL2, E2F, and toll-like receptor signaling. We report results of a phase 1b dose-escalation study of the novel, subcutaneous BET inhibitor RO6870810 (RO) combined with the BCL-2 inhibitor venetoclax, and rituximab, in recurrent/refractory DLBCL. RO was delivered for 14 days of a 21-day cycle, whereas venetoclax was delivered continuously. A 3 + 3 escalation design was used to determine the safety of the RO+venetoclax doublet; rituximab was added in later cohorts. Thirty-nine patients were treated with a median of 2.8 cycles (range, 1-11). Dose-limiting toxicities included grade 3 febrile neutropenia, grade 4 diarrhea, and hypomagnesemia for the doublet; and grade 3 hyperbilirubinemia and grade 4 diarrhea when rituximab was added. The doublet maximum tolerated dose (MTD) was determined to be 0.65 mg/kg RO+600 mg venetoclax; for RO+venetoclax+rituximab, the MTDs were 0.45 mg/kg, 600 mg, and 375 mg/m2, respectively. The most frequent grade 3 and 4 adverse events were neutropenia (28%) and anemia and thrombocytopenia (23% each). Responses were seen in all cohorts and molecular subtypes. Sustained decreases in CD11b on monocytes indicated pharmacodynamic activity of RO. Overall response rate according to modified Lugano criteria was 38.5%; 48% of responses lasted for ≥180 days. Complete response was observed in 8 patients (20.5%). Optimization of the treatment schedule and a better understanding of predictors of response would be needed to support broader clinical use. This trial is registered on www.clinicaltrials.gov as NCT03255096.
© 2021 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Figures
References
- Pérez-Salvia M, Esteller M. Bromodomain inhibitors and cancer therapy: from structures to applications. Epigenetics. 2017;12(5):323-339.
- Ramadoss M, Mahadevan V. Targeting the cancer epigenome: synergistic therapy with bromodomain inhibitors. Drug Discov Today. 2018;23(1):76-89.
- Delmore JE, Issa GC, Lemieux ME, et al. . BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146(6):904-917.
- Leal AS, Williams CR, Royce DB, Pioli PA, Sporn MB, Liby KT. Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer. Cancer Lett. 2017;394:76-87.
- Ceribelli M, Kelly PN, Shaffer AL, et al. . Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. Proc Natl Acad Sci USA. 2014;111(31):11365-11370.
- Zhu H, Bengsch F, Svoronos N, et al. . BET Bromodomain inhibition promotes anti-tumor immunity by suppressing PD-L1 expression. Cell Rep. 2016;16(11):2829-2837.
- Hogg SJ, Vervoort SJ, Deswal S, et al. . BET-bromodomain inhibitors engage the host immune system and regulate expression of the immune checkpoint ligand PD-L1. Cell Rep. 2017;18(9):2162-2174.
- Cioffi M, Trabulo SM, Vallespinos M, et al. . The miR-25-93-106b cluster regulates tumor metastasis and immune evasion via modulation of CXCL12 and PD-L1. Oncotarget. 2017;8(13):21609-21625.
- Chapuy B, McKeown MR, Lin CY, et al. . Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. [published correction appears in Cancer Cell. 2014;25(4):545–546] Cancer Cell. 2013;24(6):777-790.
- Petrich AM, Gandhi M, Jovanovic B, et al. . Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014;124(15):2354-2361.
- Herrera AF, Mei M, Low L, et al. . Relapsed or refractory double-expressor and double-hit lymphomas have inferior progression-free survival after autologous stem-cell transplantation. J Clin Oncol. 2017;35(1):24-31.
- Johnson NA, Slack GW, Savage KJ, et al. . Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3452-3459.
- Green TM, Young KH, Visco C, et al. . Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3460-3467.
- Shapiro GI, LoRusso P, Dowlati A, et al. . A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma. Br J Cancer. 2021;124(4):744-753.
- Cheson BD, Fisher RI, Barrington SF, et al. ; United Kingdom National Cancer Research Institute . Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-3068.
- Davids MS, Roberts AW, Seymour JF, et al. . Phase I first in human study of venetoclax in patients with relapsed or refractory Non-Hodgkin lymphoma. J Clin Oncol. 2017;35(8):826-833.
- Johnson-Farley N, Veliz J, Bhagavathi S, Bertino JR. ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in “double hit” lymphoma cells. Leuk Lymphoma. 2015;56(7):2146-2152.
- Lewin J, Soria JC, Stathis A, et al. . Phase Ib trial with birabresib, a small-molecule inhibitor of bromodomain and extraterminal proteins, in patients with selected advanced solid tumors. J Clin Oncol. 2018;36(30):3007-3014.
- Piha-Paul SA, Hann CL, French CA, et al. . Phase 1 study of molibresib (GSK525762), a bromodomain and extra-terminal domain protein inhibitor, in NUT carcinoma and other solid tumors. JNCI Cancer Spectr. 2019;4(2):pkz093.
- Cheson BD, Nowakowski G, Salles G. Diffuse large B-cell lymphoma: new targets and novel therapies. Blood Cancer J. 2021;11(4):68.
Source: PubMed